Clinical Trial Update: Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial update for toripalimab in local-regional recurrent nasopharyngeal carcinoma; recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Cancer Hospital of Guangxi Medical University | Conditions: Recurrent Nasopharyngeal Carcinoma | Phase 3 | Status: RECRUITING